{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:04:02Z","timestamp":1771661042326,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We describe five cases of severe necrotizing vasculitis following the RNA-based vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including four relapsing anti neutrophil cytoplasmic antibodies (ANCA) vasculitis, 27 days (1\u201360) after vaccination and one patient with quiescent chronic hepatitis B and de novo polyarteritis nodosa (PAN) 21 days after vaccination. Ten other cases were reported to the French national pharmacovigilance database: six patients with ANCA-associated vasculitis and four patients with PAN (first symptoms 19 days on average after vaccination). Five of these 10 patients developed kidney dysfunction. In conclusion, coronavirus disease 2019 (COVID-19) vaccines can be associated with de novo or recurrent ANCA vasculitis or PAN. Attention should be paid to patients with known ANCA vasculitis or patients with a history of hepatitis B infection.<\/jats:p>","DOI":"10.1093\/ckj\/sfab285","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T20:13:13Z","timestamp":1639685593000},"page":"560-563","source":"Crossref","is-referenced-by-count":22,"title":["<i>De novo<\/i> and relapsing necrotizing vasculitis after COVID-19 vaccination"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-6148","authenticated-orcid":false,"given":"Alexandre","family":"Fillon","sequence":"first","affiliation":[{"name":"Service de n\u00e9phrologie-hypertension art\u00e9rielle, dialyses, transplantation r\u00e9nale, CHU Bretonneau, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicte","family":"Sautenet","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie-hypertension art\u00e9rielle, dialyses, transplantation r\u00e9nale, CHU Bretonneau, Tours, France"},{"name":"SPHERE INSERM 1246, Universit\u00e9 de Tours, Universit\u00e9 de Nantes, Tours, France"},{"name":"Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Barbet","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie-hypertension art\u00e9rielle, dialyses, transplantation r\u00e9nale, CHU Bretonneau, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Moret","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie-hypertension art\u00e9rielle, dialyses, transplantation r\u00e9nale, CHU Bretonneau, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve Marie","family":"Thillard","sequence":"additional","affiliation":[{"name":"CHRU de Tours, Centre R\u00e9gional de Pharmacovigilance Centre Val de Loire, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie Pierre","family":"Jonville-B\u00e9ra","sequence":"additional","affiliation":[{"name":"SPHERE INSERM 1246, Universit\u00e9 de Tours, Universit\u00e9 de Nantes, Tours, France"},{"name":"CHRU de Tours, Centre R\u00e9gional de Pharmacovigilance Centre Val de Loire, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Michel","family":"Halimi","sequence":"additional","affiliation":[{"name":"Service de n\u00e9phrologie-hypertension art\u00e9rielle, dialyses, transplantation r\u00e9nale, CHU Bretonneau, Tours, France"},{"name":"Investigation Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), France"},{"name":"EA 4245, Universit\u00e9 Fran\u00e7ois-Rabelais, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"2022022210494528700_bib1","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2022022210494528700_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"2022022210494528700_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40620-021-01091-1","article-title":"Minimal change disease following vaccination for SARS-CoV-2","volume":"34","author":"Mancianti","year":"2021","journal-title":"J Nephrol"},{"key":"2022022210494528700_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.ajkd.2021.03.010","article-title":"Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine","volume":"78","author":"Lebedev","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022022210494528700_bib5","first-page":"238","article-title":"A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination","volume-title":"Kidney Int","author":"Rahim","year":"2021"},{"key":"2022022210494528700_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ajkd.2021.06.004","article-title":"De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far?","volume":"78","author":"Bomback","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022022210494528700_bib7","doi-asserted-by":"crossref","first-page":"107970","DOI":"10.1016\/j.intimp.2021.107970","article-title":"Autoimmune phenomena following SARS-CoV-2 vaccination","volume":"99","author":"Ishay","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2022022210494528700_bib8","article-title":"Kidney complications following COVID-19 vaccination; a review of the literature","author":"Hassanzadeh","year":"","journal-title":"J Nephropharmacol"},{"key":"2022022210494528700_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2021.06.016","article-title":"ANCA-associated vasculitis following the Pfizer-BioNTech COVID-19 vaccine","volume":"78","author":"Shakoor","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022022210494528700_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume-title":"iScience","author":"Ndeupen","year":"2021"},{"key":"2022022210494528700_bib11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"2022022210494528700_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2020.01.011","article-title":"ANCA associated vasculitis","volume":"74","author":"Salvador","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2022022210494528700_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.2020060804","article-title":"COVID-19-associated glomerular disease","volume":"32","author":"Shetty","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2022022210494528700_bib14","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2020060802","article-title":"Kidney biopsy findings in patients with COVID-19","volume":"31","author":"Kudose","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022022210494528700_bib15","first-page":"780","article-title":"Anti-glomerular basement membrane disease during the COVID-19 pandemic","volume-title":"Kidney Int","author":"Prendecki","year":"2020"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfab285\/42247029\/sfab285.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/3\/560\/42576204\/sfab285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/3\/560\/42576204\/sfab285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T10:53:40Z","timestamp":1645527220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/3\/560\/6470653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,12,20]]},"published-print":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfab285","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2021,12,20]]}}}